Via Yahoo Finance

ZURICH (Reuters) – Swiss drugmaker Novartis <NOVN.S> on Tuesday declined to comment on a media report that it is considering an offer for U.S. biotechnology company The Medicines Co <MDCO.O>.

Novartis is courting the maker of investigational drugs for cardiovascular conditions including atherosclerosis, or hardening of the arteries, Bloomberg reported, citing people familiar with the matter. The Medicines Co has a market capitalisation of nearly $4.7 billion after the shares have more than tripled in value this year.

(Reporting by John Miller; Editing by Michael Shields)

READ ALSO  The Trial Of Citizen Trump Would Raise Serious Constitutional Questions